In this video from Muscular Dystrophy UK, patients, caregivers and medical professionals talk about some of the best practices that should be adopted when it comes to the treatment and management of muscle-wasting diseases such as muscular dystrophy and spinal muscular atrophy (SMA). They explain how many…
A new article reviewing the effect of Duchenne muscular dystrophy (DMD) on heart function has been published in the Journal of Neuromuscular Diseases. The article titled “Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy” proposes a classification for the effect of the disease on the heart and outlines the therapeutic management techniques against heart failure.
Bone health varies greatly among patients with facioscapulohumeral muscular dystrophy (FSHD), according to the results of a small group study, and tests for strength and functionality may identify those with higher risks for decreased bone health. The study “Bone Health in Facioscapulohumeral Muscular Dystrophy: A Cross-Sectional Study” was published…
Deflazacort (Emflaza) is a drug used in the treatment of Duchenne muscular dystrophy (DMD). It’s generally given to patients five years and older and is a type of corticosteroid precursor which acts as an immunosuppressant and anti-inflammatory medication. Read our five tips for emotionally coping with Duchenne muscular dystrophy. Conducted in…
What’s your nighttime routine like? In this humorous video from Gifted Lift, Lauren gives us a sneak peek into her nighttime routine as a person with a chronic illness. Here are some exercises and stretches adapted for muscular dystrophy patients. Having a healthy snack, enjoying life to the fullest, checking in with friends,…
Administration of Inspra (eplerenone) to young boys with Duchenne muscular dystrophy (DMD) improves their heart function and stabilizes it in older boys, a recent study shows. The study “Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial” was published in the Orphanet…
The U.S. Food and Drug Administration (FDA) acknowledged the filing over protest of PTC Therapeutics’ new drug application (NDA) for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The FDA granted Translarna standard review and assigned a target date of Oct. 24, 2017…
The natural sugar fructose, commonly found in fruits and vegetables, may improve a type of treatment for Duchenne muscular dystrophy (DMD), according to researchers. The study, “Fructose Promotes Uptake and Activity of Oligonucleotides With Different Chemistries in a Context-dependent Manner in mdx Mice,” was published in the journal Molecular…
In this animated video from the Parent Project Muscular Dystrophy, Tim and Moby talk about Duchenne muscular dystrophy in a way that children of all ages can understand. The cartoon duo explains that Duchenne muscular dystrophy (DMD) affects approximately one in 3,500 boys and they are usually diagnosed between the ages…
Tens of thousands of businesses across the United States are taking part in this year’s 35th annual Muscular Dystrophy Association (MDA) Shamrocks campaign, which aims to raise funds for research and support programs to help people with muscular dystrophy. The MDA Shamrocks campaign is the country’s largest St. Patrick’s Day fundraising…
Get regular updates to your inbox.